Global Tick-borne Encephalitis Vaccine Market Size By Type (European TBE Virus, Far Eastern TBE Virus), By Application (Pediatric Vaccines, Adult Vaccines), By Region, And Segment Forecasts, 2023 to 2...

The Global Tick-borne Encephalitis (TBE) Vaccine Market was valued at USD 367 million in 2023 and is projected to reach USD 631 million by 2031, growing at a CAGR of 7.0% during the forecast period (2023–2031). The increasing prevalence of tick-borne encephalitis in endemic regions, rising awareness about preventive vaccination, and growing travel to high-risk areas are key factors fueling market expansion. Additionally, government-led immunization programs and public health initiatives in countries like Austria, Germany, and parts of Asia are significantly contributing to vaccine uptake.

Drivers

1. Rising Incidence of TBE in Endemic Regions

Climate change and increased outdoor recreational activities have expanded tick habitats, contributing to a rise in TBE cases across Europe and parts of Asia. This rise in disease burden is directly influencing vaccine demand.

2. Government Vaccination Programs

National immunization campaigns and recommendations by health authorities such as WHO and ECDC have encouraged higher vaccine coverage in high-risk areas.

3. Increased International Travel to Endemic Zones

Tourists visiting forested areas in endemic countries are increasingly advised to get vaccinated, boosting sales of pre-travel TBE vaccines.

Restraints

1. Limited Awareness in Non-Endemic Regions

Outside of endemic zones, general awareness of TBE and the availability of vaccines remains low, limiting global market penetration.

2. High Cost of Multidose Regimens

The multi-dose nature and periodic booster requirements of TBE vaccines can lead to higher costs and reduce compliance, particularly in low-income populations.

Opportunity

1. Expansion into Emerging Markets

As surveillance and diagnostic capabilities improve in developing regions, new opportunities emerge for introducing TBE vaccination as part of routine immunization.

2. Development of Single-Dose or Combination Vaccines

Innovation in vaccine delivery—such as single-dose formulations or combining TBE with other vector-borne disease vaccines—could significantly improve uptake and market size.

Market by System Type Insights

Based on system type, the Inactivated Vaccine segment held the dominant market share in 2023. These vaccines, such as FSME-IMMUN and Encepur, are widely used in Europe and have proven safety and efficacy. The Recombinant Vaccine segment is expected to witness the fastest growth due to ongoing R&D and potential regulatory approvals, offering new alternatives with fewer side effects and simplified dosing schedules.

Market by End-use Insights

In terms of end-use, the Public Health Institutions segment accounted for the largest market share in 2023. Governmental immunization efforts and school-based vaccination programs in countries like Austria and Switzerland contribute to this dominance. The Travel Clinics segment is expected to grow rapidly, driven by increased travel to endemic regions and preventive health awareness among tourists.

Market by Regional Insights

Europe dominated the global tick-borne encephalitis vaccine market in 2023, with countries such as Austria, Germany, and Switzerland showing high vaccine uptake due to longstanding government recommendations. Asia-Pacific is emerging as a key growth region, particularly in Russia and parts of China, where incidence rates are high. North America holds potential for growth, especially as awareness increases among outdoor enthusiasts and travelers.

Competitive Scenario

Key players in the global tick-borne encephalitis vaccine market include Pfizer Inc., Bavarian Nordic A/S, Chumakov Federal Scientific Center, Valneva SE, and Enyo Pharma. Companies are focusing on geographic expansion, product innovation, and collaboration with public health agencies.

In 2023, Pfizer received expanded approval for FSME-IMMUN in younger age groups in multiple European countries.

Bavarian Nordic launched clinical trials for a next-generation recombinant TBE vaccine in 2024.

Valneva partnered with health ministries to supply Encepur to public immunization programs across Central Europe.

Scope of Work – Global Tick-borne Encephalitis Vaccine Market

Key Market Developments

March 2023 – Pfizer expanded its FSME-IMMUN vaccine use to children aged 1–5 years in the EU.

October 2023 – Bavarian Nordic received funding from the EU to develop a recombinant TBE vaccine.

May 2024 – Valneva SE announced a new multi-year contract with Germany’s Federal Ministry of Health to supply Encepur for national immunization.

FAQs

What is the current market size of the Global Tick-borne Encephalitis Vaccine Market?

The market was valued at USD 367 million in 2023.

What is the major growth driver of the Global Tick-borne Encephalitis Vaccine Market?

The primary growth driver is the rising incidence of TBE in endemic regions, boosting demand for preventive vaccination.

Which is the largest region during the forecast period in the Global Tick-borne Encephalitis Vaccine Market?

Europe is the largest regional market due to established immunization programs and high disease prevalence.

Which segment accounted for the largest market share in the Global Tick-borne Encephalitis Vaccine Market?

The Inactivated Vaccine segment held the largest market share in 2023.

Who are the key market players in the Global Tick-borne Encephalitis Vaccine Market?

Major players include Pfizer Inc., Bavarian Nordic A/S, Valneva SE, and Chumakov Federal Scientific Center.